UK Companies House feature
MODERNA BIOTECH MANUFACTURING UK LTD
Profile
- Company number
- 14200882
- Status
- Active
- Incorporation
- 2022-06-28
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Accounts
Pending extraction
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“received written support from its parent and ultimate parent to maintain going concern status through at least December 2026. ... Based on the liquidity of the Group and future forecasts, the directors believe that the Group has sufficient liquidity to meet the Company's short and medium-term business needs and obligations. ... the directors continue to adopt the going concern basis in preparing the financial statements.”
Significant events
- “On 1 January 2024, a group of 26 UK-based employees was transferred from Moderna Biotech Distributor UK Ltd to Moderna Biotech Manufacturing UK Ltd under the Transfer of Undertakings (Protection of Employment) Regulations 2006 (TUPE).”
- “The Company achieved Facility Readiness in September 2025, triggering an £80 million milestone payment under its agreement with the UK Government.”
- “Construction of the R&D building was completed in April 2025, and the drug substance manufacturing building was finalized in September 2025.”
- “The Company's loan facility was expanded to £200 million during the year to further support its operational and strategic objectives.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
4 active · 3 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| KEANE, Ciaran John | Secretary | 2025-10-20 | — | — |
| BROUGHTON SECRETARIES LIMITED | Corporate Secretary | 2022-06-28 | — | — |
| KEANE, Ciaran John | Director | 2025-10-20 | Jun 1994 | British |
| LARKIN, Jed Davidson | Director | 2024-06-10 | Aug 1970 | American |
Show 3 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| SANDSTROM, Brian Taylor | Secretary | 2022-06-28 | 2025-10-20 |
| BRACKMANN, Christoph | Director | 2022-06-28 | 2024-06-10 |
| SANDSTROM, Brian Taylor | Director | 2022-06-28 | 2025-10-20 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Moderna Biotech Uk Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-06-28 | Active |
Filing timeline
Last 16 of 16 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-04-30 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2025-10-27 | AA | accounts | accounts with accounts type full |
| 2025-10-22 | AP01 | officers | appoint person director company with name date |
| 2025-10-22 | AP03 | officers | appoint person secretary company with name date |
| 2025-10-22 | TM01 | officers | termination director company with name termination date |
| 2025-10-22 | TM02 | officers | termination secretary company with name termination date |
| 2025-06-25 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-12-19 | AA | accounts | accounts with accounts type small |
| 2024-07-03 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-06-18 | AP01 | officers | appoint person director company with name date |
| 2024-06-18 | TM01 | officers | termination director company with name termination date |
| 2023-10-12 | AA | accounts | accounts with accounts type small |
| 2023-07-17 | CH01 | officers | change person director company with change date |
| 2023-06-30 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-08-01 | AA01 | accounts | change account reference date company current shortened |
| 2022-06-28 | NEWINC | incorporation | incorporation company |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory